Corporate Information
CEO Message
Mission
Corporate Information
Corporate Governance
Business
Stemrim History
About “Regeneration-Inducing Medicine
™
”
What is “Regeneration-Inducing Medicine
™
”?
Issues of Conventional Cell Therapy
The Superiority of “Regeneration-Inducing Medicine
™
”
Business
Areas of Disease and Pipeline
“Regeneration-Inducing Medicine
™
”
Autologous cell sampling devices for medical treatment
Stem cells gene therapy
Research Paper
Investor Relations
COO Message
Investor News
ESG
Financial Data
Investor Library
Investor Calendar
Analyst Coverage
Stock Prices
Investor Relations
Timely Disclosure Information
April 09, 2025
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)
April 03, 2025
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic articular Cartilage Deficiency Syndrome, Osteoarthritis, and Osteochondritis dissecans
April 02, 2025
StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke
March 03, 2025
StemRIM Announces the Protocol Amendment for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke
January 15, 2025
StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms
Click here for past list
StemRIM
>
Investor Relations
>
Investor Library
>
Timely Disclosure Information
